**Supplementary figures**

Supplementary figure 1. Determination of RBD IgG reactivity by assay date. Optical

density (O.D.) at 405 nm with known positive and pre-2019 serum samples is presented.

Supplementary figure 2. Microneutralization of SARS-CoV-2. Representative images of

focus-based microneutralization of SARS-CoV-2/WA-1/2020 by COVID-19 serum, but not by

pre-pandemic serum. Also included are mock infected and virus-only controls.

(a)

(b)

Supplementary figure 3. | RBD-S and spike IgG responses in COVID-19 patients. (a) RBD-IgG reactivity for each patient by timepoint after onset of symptoms was determined by ELISA. Values over threshold (indicated by dashed line) are indicated as RBD-S-positive and those under threshold as RBD-S-negative. **(b)** Patient-specific endpoint titers for spike IgG are plotted by day after symptoms onset and according to RBD-S IgG positivity by timepoint.

Supplementary figure 4. | SARS-CoV-2 neutralization in COVID-19 patients. Focus reduction (by 50%) neutralization titers ($FRNT_{50}$) was determined by serial dilution of serum samples from COVID-19 patients taken at different times post onset of symptoms. RBD-IgG reactivity is indicated for each sample. FRNT50 cutoff is indicated by dotted line and was set at 1:50 which was the lowest dilution tested. $FRNT_{50}$-negative samples were assigned a titer of 1:20.

Supplementary figure 5. | Spike IgG responses by antibody isotype in individual COVID-19 patients. Serum was diluted 1:100 and tested for spike reactivity by ELISA and OD 405nm is shown.

Supplementary figure 6. | Anti-RBD-S IgM and IgA responses in COVID-19 patients by biological sex and hospitalization type. Serum was diluted 1:100 and tested for RBD-S reactivity by ELISA and reactivities for IgM (**a, c**) and IgA (**b, d**) and plotted as a function of biological sex (**a, b**) and type of hospitalization (ICU or non-ICU, **c, d**). Boxplots show the median, 95% confidence level of OD 405nm from all individual samples. The Mann-Whitney *U*-test *P*-value is shown.